Navigation Links
Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2,Predicts Heart Disease Risk in Metabolic Syndrome Patients

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Study results show that elevated lipoprotein-associated phospholipase A2 (Lp-PLA2), a cardiovascular-specific inflammatory enzyme associated with unstable plaque that can lead to heart attack and stroke, is especially predictive of heart disease risk in patients with the metabolic syndrome--a serious medical condition that affects nearly 50 million Americans. The results, which were presented yesterday at the American College of Cardiology's annual scientific session, confirm previous findings demonstrating the association between elevated Lp-PLA2 and coronary heart disease.

Investigators at the University of Utah in Salt Lake City used the PLAC test from diaDexus to measure Lp-PLA2 levels in blood samples from almost 1,500 patients enrolled in the Intermountain Heart Collaborative Study. The patients also underwent coronary angiography to determine the presence of heart disease and were tracked for up to 10 years. Results showed that Lp-PLA2 was a clinically important predictor of heart disease and future death in patients with the metabolic syndrome, a dangerous precursor to diabetes characterized by high blood pressure, high triglycerides, high fasting blood glucose, low high-density lipoprotein, and small, dense low-density lipoprotein. Lp-PLA2 also predicted heart disease death risk in non-metabolic syndrome patients.

According to Richard Lanman, M.D., diaDexus' chief medical officer, the findings are important because of the large number of patients with the metabolic syndrome who may be at significantly increased risk for diabetes, stroke, and heart disease. "Interest in the metabolic syndrome has been increasing along with Americans' growing waistlines," Lanman said. "This study confirms earlier results indicating that elevated Lp-PLA2 is independent from and additive to the increased cardiovascular risk associated with insulin resistance. The addition al information about rupture-prone plaque provided by Lp-PLA2 can help identify which metabolic syndrome patients should be targeted with more aggressive treatment."

A second study presented at the meeting focused on treatment of 55 metabolic syndrome patients with elevated levels of Lp-PLA2 and triglycerides. The results presented by Dr. Robert Rosenson of the University of Michigan showed that three months of treatment with fenofibrate (160 mg/day) reduced Lp-PLA2 levels measured with the PLAC test. Lanman said these findings highlight the opportunity for plaque stabilization with lipid-modifying medication when patients with the metabolic syndrome also have elevated Lp-PLA2. "The PLAC test identifies patients who benefit from lipid-modifying therapy such as fenofibrate to help prevent cardiovascular events," he said.

diaDexus, Inc., a privately held biotechnology company based in South San Francisco, Calif., is focused on the discovery, development, and commercialization of innovative, patent-protected diagnostic products with high clinical value. The PLAC test is a simple blood test that has been cleared for marketing by the Food and Drug Administration as an aid in predicting risk for coronary heart disease and ischemic stroke associated with atherosclerosis. In addition to the PLAC test, diaDexus is developing a pipeline of novel cancer diagnostic tests. For information, visit www.plactest.com or www.diaDexus.com.

Note to editors: The American College of Cardiology's 56th annual scientific session is being held at the Ernest N. Morial Convention Center in New Orleans, March 24-27, 2007. diaDexus' booth number is 1232. For copies of the abstracts, please contact Barbara Sullivan at 714/374-6174.

Contact

Sullivan & Associates
Barbara Sullivan, 714-374-6174
bsullivan@sullivanpr.com
or
diaDexus, Inc.
Christina Andrian, 650-246-6476 candrian@diadexus.com


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... N.Y. , Feb. 20, 2017  Henry ... of health care products and services to ... today announced that it has entered into ... Surgical (SAS), a leading U.S. distributor of ... dental anesthesiologists, and periodontists. SAS offers controlled ...
(Date:2/20/2017)... Wis. , Feb. 20, 2017  National ... MEDITECH to integrate the company,s CareSelect Imaging platform ... This formal agreement sets the technical foundation for ... access NDSC,s CareSelect Imaging Clinical Decision Support Mechanism ... to work directly with and support the integration ...
(Date:2/20/2017)... 2017 Seal Shield LLC ( Jacksonville, ... mobile device management and disinfection, the ElectroClave™, to the ... in Orlando, Fla. from February ... have become commonplace in today,s healthcare landscape, but with ... concerns, including the disinfection and tracking of these devices.  ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... 20, 2017 , ... Chuck E. Cheese’s® and Center for Autism and Related ... Chuck E. Cheese’s locations throughout New England, New York and New Jersey to provide ... the fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. , After ...
(Date:2/19/2017)... ... , ... Braun Industries will be participating as an exhibitor at EMS Today ... February 23-25, 2017 at the Calvin L. Rampton Salt Palace Convention Center in Salt ... ambulances on display. , “JEMS is a leader in EMS news and ...
(Date:2/18/2017)... , ... February 17, 2017 ... ... for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 ... manufacturers looking to reduce their regulatory burden? Pay dividends in enhanced and ...
(Date:2/18/2017)... , ... February 17, 2017 , ... Park Cities Pet ... Behave” Show on the Pet Life Radio network. The episode, which was posted ... of topics including: what factors led to Park Cities Pet Sitter’s being awarded the ...
(Date:2/17/2017)... TN (PRWEB) , ... February 17, 2017 , ... ... mobility has not kept pace. Enovate Medical has introduced an innovative workstation designed ... years of supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, highly ...
Breaking Medicine News(10 mins):